Evidence supporting the use of bone morphogenetic proteins for spinal fusion surgery

Expert Review of Medical Devices

Volumn 5, Issue 1, 2008, Pages 75-84

  Robinson, Yohan ^a   Heyde, Christoph E ^a   Tschöke, Sven K ^a   Mont, Michael A ^b   Seyler, Thorsten M ^c   Ulrich, Slif D ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Bone graft; Bone morphogenetic protein; Spinal fusion

Indexed keywords

BONE MORPHOGENETIC PROTEIN; INFUSE; PUTTY; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; UNCLASSIFIED DRUG;

BONE DEVELOPMENT; BONE GRAFT; BONE PROSTHESIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ECTOPIC ORGAN; FOLLOW UP; FRACTURE HEALING; FRACTURE NONUNION; HEMATOMA; HUMAN; HYPEROSTOSIS; INFECTION; INFLAMMATION; INJECTION SITE PAIN; MORBIDITY; NONHUMAN; OPERATION DURATION; OSSIFICATION; PATIENT SATISFACTION; POSTOPERATIVE EDEMA; REVIEW; SIDE EFFECT; SPINE FUSION; SPINE SURGERY; SURGICAL APPROACH; SURGICAL TECHNIQUE; VERTEBRAL CANAL STENOSIS;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CLINICAL TRIALS AS TOPIC; HUMANS; LUMBAR VERTEBRAE; SPINAL DISEASES; SPINAL FUSION;

EID: 38049117881     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.5.1.75     Document Type: Review

References (44)

1. Urist MB. Bone: formation by autoinduction. Science 150, 893-899 (1965).
2. Wozney JM, Rosen V, Celeste AJ et al. Novel regulators of bone formation: molecular clones and activities. Science 242, 1528-1534 (1988).
3. Brown A, Stock G, Patel AA, Okafor C, Vaccaro A. Osteogenic protein-1: a review of its utility in spinal applications. Bio Drugs 20, 243-251 (2006).
4. Cheng H, jiang W, Phillips FM et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J. Bone Joint Surg. Am. 85A, 1544-1552 (2003).
5. De Biase P. Capanna R. Clinical applications of BMPs. Injury 36, S43-S46 (2005).
6. Shields LB, Raque GH, Glassman SD et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 31, 542-547 (2006).
7. Cook SD, Dalton JE, Tan EH, Whitecloud TS 3rd, Rueger DC. In vivo. evaluation of recombinant human osteogenic protein (rhOP- 1) implants as a bone graft substitute for spinal fusions. Spine 19, 1655-1663 (1994).
8. Schimandle JH, Boden SD, Hutton WC. Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 20, 1326-1337 (1995).
9. Boden SD, Martin GJ Jr, Horton WC, Truss TL, Sandhu HS. Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J. Spinal Disord. 11, 95-101 (1998).
10. Hecht BP, Fischgrund JS, Herkowitz HN, Penman L, Toth JM, Shirkhoda A. The use of recombinant human bone morphogenetic protein 2 (rhBMP-2) to promote spinal fitsion in a nonhuman primate anterior interbody fusion model. Spine 24, 629-636 (1999).
11. Akamaru T, Suh D, Boden SD, Kim HS, Minamide A, Louis-Ugbo J. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine 28, 429-434 (2003).
12. Patel VV, Zhao L, Wong P et al. An in vitro and in vivo analysis of fibrin glue use to control bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth. Spine J. 6, 397-403 (2006).
13. Kandziora F, Bail H, Schmidmaier G et al. Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors. J. Neurosurg. 97, S40-S48 (2002)
14. Namikawa T. Terai H, Suzuki E et al. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and β-tricalcium phosphate in a rabbit model. Spine 30, 1717-174 (2005).
15. Minamide A, Kawakami M, Hashizume H, Sakata R, Yoshida M, Tamaki T. Experimental study of carriers of bone morphogenetic protein used for spinal fusion. J. Orthop. Sci. 9, 142-151 (2004).
16. Barnes B, Boden SD, Louis-Ugbo J et al. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine 30, 1127-1133 (2005).
17. Zhao J, Zhao DY, Shen AG et al. Promoting lumbar spinal fusion by adenovirus-mediated bone morphogenetic protein-4 gene therapy. Chin. J. Traumatol. 10, 72-76 (2007).
18. Zhu W, Rawlins BA, Boachie-Adjei O et al. Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J. Bone Miner. Res. 19, 2021-2032 (2004).
19. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 25, 376-381 (2000).
20. Haid RW Jr, Branch CL Jr, Alexander JT, Burkus JK. Posterior lumbar interbody fision using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 4, 527-538 (2004).
21. Mummaneni PV, Pan J, Haid RW, Rodts GE. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J. Neurosurg. Spine 1, 19-23 (2004).
22. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27, 2662-2673 (2002).
23. Kanayama M, Hashimoto T, Shigenobu, Yamane S, Bauer TW, Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein- 1 (Op-1) versus local autograft mith ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine 31, 1067-1074 (2006).
24. Vaccaro AR, Whang PG, Patel T et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J. (2007) (Epub ahead of print).
25. Kuklo TR, Rosner MK, Polly DW Jr. Computerized tomography evaluation of a resorbable implant after transforaminal lumbar interbody fusion. Neurosurg. Focus 6, E10 (2004).
26. Lanman TH, Hopkins TJ. Lumbar interbody fusion after treatment with recombinant human bone morphogenetic protein-2 added to poly(L-lactide-co-D,L-lactide) bioresorbable implants. Neurosurg. Focus 16, E9 (2004).
27. Johnsson R, Stromquist B, Aspenberg P. Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine 27, 2654-2661 (2002).
28. Sasso RC, LeHuec JC, Shaffrey C; Spine Interbody Research Group. Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment. J. Spinal Disord. Tech. 18, S77-S81 (2005).
29. Delawi D, Dhert WJ, Castelein RM, Verbout AJ, Oner FC. The incidence of donor site pain after bone graft harvesting from the posterior iliac crest may be overestimated: a study on spine fracture patients. Spine 32, 1865-1868 (2007).
30. Hacker RJ, Cauthen JC, Gilbert TJ, Griffith SL. A prospective randomized multicenter clinical evaluation of an anterior cervical fusion cage. Spine 25, 2646-2654 (2000).
31. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 28, 1219-1224 (2003).
32. Boakye M, Mummaneni PV, Garrett M, Rodts G, Haid R. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J. Neurosurg. Spine 2, 521-525 (2005).
33. Smith-Hammond CA, New KC, Pietrobon R, Curtis DJ, Scharver CH, Turner DA. Prospective analysis of incidence and risk factors of dysphagia in spine surgery patients: comparison of anterior cervical, posterior cervical, and lumbar procedures. Spine 29, 1441-1446 (2004).
34. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 27, S40-S48 (2002).
35. Paramore CG, Lauryssen C, Rauzzino MJ et al. The safety of OP-1 for lumbar fusion with decompression - a canine study. Neurosurgery 44, 1151-1155 (1999).
36. Kawakami M, Hashizume H, Matsumoto T et al. Safety of epidural administration of osteogenic protein- 1 (OP-1/BMP-7): behavioral and macroscopic observation. Spine 32, 1388-1393 (2007).
37. Alt V, Haas H, Rauschmann MA et al. [Health-economic consideratins for the use of BMP-2 for spinal surgery in Germany]. Z. Orthop. Ihre Grenzgeb. 144, 577-582 (2006).
38. Garrison KR, Donell S, Ryder J et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol. Assess. 11, 1-168 (2007).
39. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston RA. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 27, 2396-2408 (2002).
40. Villavicencio AT, Burneikiene S, Nelson EL, Bulsara KR, Favors M, Thramann J. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J. Neurosurg. Spine 3, 436-443 (2005).
41. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 31, 2534-2539 (2006).
42. Singh K, Smucker JD, Gill S, Boden SD. Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: a prospective CT-scan analysis at one and two years. J. Spinal Disord. Tech. 19, 416-423 (2006).
43. Slosar PJ, Josey R, Reynolds J. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes. Spine J. 7, 301-307 (2007).
44. Glassman SD, Carreon L, Djurasovic M et al. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J. 7, 44-49 (2007).